

1. Record Nr.	UNINA9910966729803321
Autore	Bais Sander
Titolo	The equations : icons of knowledge / / Sander Bais
Pubbl/distr/stampa	Cambridge, Mass., : Harvard University Press, c2005
ISBN	1-4237-4626-0
Edizione	[1st ed.]
Descrizione fisica	1 online resource (97 p.)
Disciplina	512.9/4
Soggetti	Equations, Theory of Logic, Symbolic and mathematical
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Intro -- Table of Contents -- Introduction -- The tautological toolkit -- Rise and fall: The logistic equation -- Mechanics and gravity: Newton's dynamical equations and universal law of gravity -- The electromagnetic force: The Lorentz force law -- A local conservation law: The continuity equation -- Electrodynamics: The Maxwell equations -- Electromagnetic waves: The wave equations -- Solitary waves: The Korteweg-De Vries equation -- Thermodynamics: The three laws of thermodynamics -- Kinetic theory: The Boltzmann equation -- Hydrodynamics: The Navier-Stokes equations -- Special relativity: Relativistic kinematics -- General relativity: The Einstein equations -- Quantum mechanics: The Schrödinger equation -- The relativistic electron: The Dirac equation -- The strong force: Quantum chromodynamics -- Electro-weak interactions: The Glashow-Weinberg-Salam model -- String theory: The superstring action -- Back to the future: A final perspective.
Sommario/riassunto	In this book by the renowned Dutch physicist Sander Bais, the equations that govern our world unfold in all their formal grace and their deeper meaning as core symbols of our civilization.

2. Record Nr.	UNINA9910970771503321
Titolo	The children's vaccine initiative : achieving the vision / / Violaine S. Mitchell, Nalini M. Philipose, and Jay P. Sanford, editors ; Committee on the Children's Vaccine Initiative : Planning Alternative Strategies Toward Full U.S. Participation, Division of International Health, Institute of Medicine
Pubbl/distr/stampa	Washington, D.C., : National Academy Press, 1993
ISBN	9786610196012 9781280196010 1280196017 9780309585835 030958583X 9780585143521 0585143528
Edizione	[1st ed.]
Descrizione fisica	1 online resource (xiii, 221 pages) : illustrations
Altri autori (Persone)	SanfordJay P. <1928-> MitchellViolaine S PhiliposeNalini M
Disciplina	614.4/7/083
Soggetti	Vaccination of children Vaccines Immunization of children Vaccination Children Infants Immunization Programs Child Immunization Schedule Infant
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Support provided by the Agency for International Development, the Dept. of Health and Human Services, the Pharmaceutical Manufacturers Association, the United Nations Development Program, and the World Health Organization, Children's Vaccine Initiative.

The Children's Vaccine Initiative -- Copyright -- Preface --
 Acknowledgments -- Contents -- 1 Executive Summary -- THE
 CHILDREN'S VACCINE INITIATIVE -- THE INSTITUTE OF MEDICINE
 REPORT -- COMMITTEE FINDINGS -- Resources and Infrastructure --
 Vaccine Demand and Supply -- Demand -- Supply -- Innovation --
 Investing in New and Improved Vaccines -- Stages of Vaccine
 Development -- Pilot Production -- Clinical Trials -- Scaleup and
 Large-Scale Manufacture -- Technology Transfer -- A STRATEGY TO
 ENHANCE U.S. PARTICIPATION -- NOTE -- REFERENCE -- 2 Why a
 Children's Vaccine Initiative? -- PROGRESS TOWARD UNIVERSAL
 CHILDHOOD IMMUNIZATION -- Limits of the Expanded Program on
 Immunization -- THE CHILDREN'S VACCINE INITIATIVE --
 Characteristics of CVI Vaccines -- Vaccines Should Be Single Dose --
 Vaccines Should Be Administered Near Birth -- Vaccines Should Be
 Combined in Novel Ways -- Vaccines Should Be Heat Stable -- Vaccines
 Should Be Effective Against Additional Diseases -- Vaccines Should Be
 Affordable -- Concerns About the CVI -- RELEVANCE OF THE CVI TO U.
 S. IMMUNIZATION EFFORTS -- Status of Immunization Efforts in the
 United States -- A Role for the CVI in the United States -- REFERENCES
 -- 3 Resources and Infrastructure -- RESOURCES IN THE UNITED
 STATES -- U.S. Federal Agencies and Programs -- U.S. Agency for
 International Development -- Center for Biologics Evaluation and
 Research, U.S. Food and Drug Administration -- Centers for Disease
 Control and Prevention -- U.S. Department of Defense -- National
 Institutes of Health -- National Vaccine Program -- Other Federal
 Programs -- U.S. State Vaccine Manufacturers -- Massachusetts --
 Michigan -- U.S.-Based Pharmaceutical Firms -- Connaught
 Laboratories, Inc. -- Lederle-Proxys Biologicals -- Merck & Co.,
 Inc. -- SmithKline Beecham -- Wyeth-Ayerst -- Development-Stage
 Companies.
 North American Vaccine -- MedImmune -- Univax Biologicals, Inc. --
 Nongovernmental Organizations -- The Children's Defense Fund --
 March of Dimes Birth Defects Foundation -- Rockefeller Foundation --
 Rotary Foundation -- INTERNATIONAL RESOURCES -- Multilateral
 Organizations -- Pan American Health Organization -- PAHO Revolving
 Fund -- SIREVA Project -- United Nations Development Program --
 United Nations Children's Fund -- Vaccine Independence Initiative --
 World Bank -- World Health Organization -- Expanded Program on
 Immunization -- Program for Vaccine Development -- Children's
 Vaccine Initiative -- Public-Sector Resources -- Private-Sector
 Resources -- Nongovernmental Organizations -- Task Force for Child
 Survival and Development -- Save the Children Fund -- REFERENCES --
 4 Vaccine Demand and Supply -- GLOBAL DEMAND AND SUPPLY --
 Demand -- Regional Demand -- Supply -- Procurement -- Innovation
 -- DEMAND AND SUPPLY IN THE UNITED STATES -- Demand -- Supply
 -- Pricing -- Vaccine Innovation -- NOTE -- REFERENCES -- 5
 Investing in New and Improved Vaccines -- MARKET CONSIDERATIONS
 -- Market Size -- Intellectual Property -- Patent Rights and Limitations
 -- Patents and Vaccines -- Infringement -- LIABILITY -- REFERENCES
 -- 6 Stages of Vaccine Development -- PRIORITY SETTING -- BASIC
 AND APPLIED RESEARCH -- CLINICAL EVALUATION -- LICENSURE --
 PRODUCTION -- Pilot Production -- ScaleUp and Full-Scale
 Manufacture -- Vaccine Production in Developing Countries --
 RECOMMENDATIONS FOR USE -- PROCUREMENT -- DISTRIBUTION AND
 DELIVERY -- SURVEILLANCE -- Immunization Status -- Monitoring
 Effectiveness of Vaccines -- Adverse Reactions -- Setting Priorities for
 Vaccine Use and New Vaccines -- REFERENCES -- 7 A Strategy to

Enhance U.S. Participation in the Children's Vaccine Initiative -- A
 NATIONAL VACCINE AUTHORITY -- Mission -- Functions.
 Setting Priorities and Product Characterization -- Basic Research --
 Applied Research and Exploratory Development -- Intellectual Property
 Rights -- Product Development -- Clinical Evaluation -- Regulation --
 Manufacture -- Procurement -- Monitoring and Evaluation --
 Management and Organization -- Funding -- Location -- Points to
 Consider for Locating the CVI in an Existing Federal Agency -- Options
 -- U.S. Agency for International Development -- Centers for Disease
 Control and Prevention -- U.S. Department of Defense -- U.S. Food and
 Drug Administration -- National Institutes of Health -- The National
 Vaccine Program -- Independent Organization -- NOTE -- REFERENCES
 -- Appendixes -- A Relevant Intellectual Property Rights Law --
 PATENTS -- Rights and Limitations -- Infringement -- Potential
 Barriers and Incentives -- First-to-File Versus First-to-Invent --
 Backlog in the Patent and Trademark Office -- Costs -- Disclosure to
 Government Agencies -- Relevant Legislation and Terminology -- Drug
 Price Competition and Patent Term Restoration Act of 1984 (P.L. 98-
 417) -- Omnibus Trade and Competitiveness Act (P.L. 100-418) --
 Grace Period -- Orphan Drug Act of 1983 (P.L. 99-91) -- Patent and
 Trademark Amendments of 1980 (P.L. 96-517) -- Experimental Use
 Exception -- TRADE SECRETS (KNOW-HOW) -- Definition --
 Confidentiality -- Rights of the Trade Secret Owner -- Rights Against
 Individuals in Privity -- Protection by Contract -- Implied
 Contract/Special Relationships -- Rights Against Third Parties --
 Additional Rights of a Trade Secret Owner -- Rights to Use Another's
 Trade Secrets -- REFERENCES -- B National Vaccine Injury
 Compensation Program -- DEFINITION AND PURPOSE -- BACKGROUND
 -- FILING A CLAIM UNDER NVICP -- KEY CHARACTERISTICS --
 REFERENCES -- C Regulatory Aspects of Vaccine Development,
 Manufacture, and Distribution -- THE LICENSURE PROCESS.
 POSTLICENSING -- Manufacture -- Distribution -- THE DRUG EXPORT
 AMENDMENTS ACT OF 1986 -- REFERENCES -- D Strategies for
 Achieving Full U.S. Participation in the Children's Vaccine Initiative --
 STRATEGY 1: RETAIN THE CURRENT SYSTEM -- Option 1: Increased
 Funding for CVI Vaccine Research -- Contribution to the Global CVI --
 Option 2: Purchase Existing Vaccines -- Contribution to the Global CVI
 -- Option 3: Improve Vaccine Delivery -- Contribution to the Global
 CVI -- STRATEGY 2: FORGING NEW PARTNERSHIPS BETWEEN THE PUBLIC
 AND PRIVATE SECTORS -- Option 1: Broker CVI R&D and Pilot
 Manufacture -- Contribution to the Global CVI -- Option 2: Develop an
 Entity with CVI-Related R&D and Pilot Manufacturing
 Capabilities -- Contribution to the Global CVI -- STRATEGY 3: EMBARK
 ON A PUBLIC-SECTOR MODEL -- Contribution to the Global CVI -- E
 Public Health Service Act (1944) -- PUBLIC LAWS-CH. 373-JULY 1, 1944
 PART F-BIOLOGICAL PRODUCTS Regulation of Biological Products --
 Interference With Officers -- Penalties for Offenses -- F National
 Vaccine Program Legislation -- TITLE XXI-VACCINES SUBTITLE 1-
 NATIONAL VACCINE PROGRAM -- Establishment -- Program
 Responsibilities -- Plan -- Report -- National Vaccine Advisory
 Committee -- Authorizations -- G Immunization Schedules -- H
 Historical Record of Vaccine Product License Holders in the United
 States -- I Working Group Participants June 11-13, 1992 -- NOTES -- J
 Committee and Staff Biographies -- K Acronyms.

Sommario/riassunto

The Children's Vaccine Initiative is an international endeavor to ensure that children throughout the world are immunized. This book notes that one of the best opportunities to address the growing problem of immunization in the United States and to improve the health of children

in developing countries lies in marshaling the vaccine development and production efforts in the United States and abroad. The book contains information on the nature and status of vaccine development and production efforts in the United States and abroad, and it recommends ways to enhance participation in the International Children's Vaccine Initiative.
